Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nick Giannoukakis

Showing results (1-10 of 76) with videos related to

Pageof 8
Sort By:
Current Opinion in Investigational Drugs (London, England : 2000)|December 3, 2003
CJC-1131. ConjuChemNick Giannoukakis
Expert Opinion on Drug Metabolism & Toxicology|May 3, 2014
Evaluation of ranirestat for the treatment of diabetic neuropathyNick Giannoukakis
Expert Opinion on Investigational Drugs|March 28, 2008
Ranirestat as a therapeutic aldose reductase inhibitor for diabetic complicationsNick Giannoukakis
Frontiers in Immunology|June 30, 2023
Tolerogenic dendritic cells in type 1 diabetes: no longer a conceptNick Giannoukakis
Current Opinion in Investigational Drugs (London, England : 2000)|May 19, 2005
Pyridoxamine (BioStratum)Nick Giannoukakis
Current Opinion in Investigational Drugs (London, England : 2000)|December 3, 2003
Fidarestat. Sanwa Kagaku/NC Curex/SankyoNick Giannoukakis
Current Opinion in Investigational Drugs (London, England : 2000)|November 2, 2005
DiaPep277 (DeveloGen)Nick Giannoukakis
Immunotherapy|September 4, 2013
Immunoregulatory dendritic cells to treat autoimmunity are ready for the clinic. Interview by Katie LockwoodNick Giannoukakis
Immunotherapy|June 4, 2013
Tolerogenic dendritic cells for Type 1 diabetesNick Giannoukakis
Current Opinion in Investigational Drugs (London, England : 2000)|June 18, 2003
Exenatide. Amylin/Eli LillyNick Giannoukakis
Pageof 8

Showing results (1-10 of 76) with videos related to

Sort By:
Pageof 8
Current Opinion in Investigational Drugs (London, England : 2000)|December 3, 2003
CJC-1131. ConjuChemNick Giannoukakis
Expert Opinion on Drug Metabolism & Toxicology|May 3, 2014
Evaluation of ranirestat for the treatment of diabetic neuropathyNick Giannoukakis
Expert Opinion on Investigational Drugs|March 28, 2008
Ranirestat as a therapeutic aldose reductase inhibitor for diabetic complicationsNick Giannoukakis
Frontiers in Immunology|June 30, 2023
Tolerogenic dendritic cells in type 1 diabetes: no longer a conceptNick Giannoukakis
Current Opinion in Investigational Drugs (London, England : 2000)|May 19, 2005
Pyridoxamine (BioStratum)Nick Giannoukakis
Current Opinion in Investigational Drugs (London, England : 2000)|December 3, 2003
Fidarestat. Sanwa Kagaku/NC Curex/SankyoNick Giannoukakis
Current Opinion in Investigational Drugs (London, England : 2000)|November 2, 2005
DiaPep277 (DeveloGen)Nick Giannoukakis
Immunotherapy|September 4, 2013
Immunoregulatory dendritic cells to treat autoimmunity are ready for the clinic. Interview by Katie LockwoodNick Giannoukakis
Immunotherapy|June 4, 2013
Tolerogenic dendritic cells for Type 1 diabetesNick Giannoukakis
Current Opinion in Investigational Drugs (London, England : 2000)|June 18, 2003
Exenatide. Amylin/Eli LillyNick Giannoukakis
Pageof 8